clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all lines of therapy, treatment regimens,...
MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on...
NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
NEW YORK, Nov. 30, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a...
AGOURA HILLS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer...
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal...
AUM302 has potential to be the first multi-kinase inhibitor class of drug in NeuroblastomaSINGAPORE and BETHESDA, Md., Nov. 30, 2022...
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy...
Recent achievements showcase company’s leadership as CRO Partner and Employer of Choice in the Asia/Pacific regionBOSTON and DURHAM, N.C., Nov. 29,...
Investigators to present efficacy and safety data of ARX788 treatment in patients with HER2+ metastatic breast cancer who have progressed...
New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical...
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents...
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of...
INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15th CTAD conference in San Francisco November...
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics...
NORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins,...
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 -...
SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid tumorsPreclinical efficacy and tolerability studies...
CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host...
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant...